title: Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study.
abstract: BACKGROUND
  The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months clopidogrel treatment among MI patients treated with PCI.
  
  
  METHODS
  Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11 680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment regimens.
  
  
  RESULTS
  The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in 3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p = 0.06).
  
  
  CONCLUSIONS
  We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months' clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.
authors.affiliation: Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65, 2900 Hellerup, Denmark. rs@heart.dk
authors.forename: Rikke
authors.initials: R
authors.lastname: Sørensen
authors.forename: Steen Z
authors.initials: SZ
authors.lastname: Abildstrom
authors.forename: Peter
authors.initials: P
authors.lastname: Weeke
authors.forename: Emil L
authors.initials: EL
authors.lastname: Fosbøl
authors.forename: Fredrik
authors.initials: F
authors.lastname: Folke
authors.forename: Morten L
authors.initials: ML
authors.lastname: Hansen
authors.forename: Peter R
authors.initials: PR
authors.lastname: Hansen
authors.forename: Jan K
authors.initials: JK
authors.lastname: Madsen
authors.forename: Ulrik
authors.initials: U
authors.lastname: Abildgaard
authors.forename: Lars
authors.initials: L
authors.lastname: Køber
authors.forename: Henrik E
authors.initials: HE
authors.lastname: Poulsen
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Gislason
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality* / Q000639:trends; D000077144:Clopidogrel; D015331:Cohort Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality* / Q000517:prevention & control; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D055502:Secondary Prevention; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000077144:Clopidogrel; D013988:Ticlopidine